Destiny Pharma Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Destiny Pharma (LON:DEST) Full Year 2023 Results

Key Financial Results

• Revenue: UK£831.6k (up 438% from FY 2022).
• Net loss: UK£5.66m (loss narrowed by 13% from FY 2022).
• UK£0.062 loss per share (improved from UK£0.093 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Destiny Pharma EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 7.3%.

The company's shares are down 13% from a week ago.

Risk Analysis

Before you take the next step you should know about the 5 warning signs for Destiny Pharma (2 make us uncomfortable!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.